Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome.

Pedro David Wendel-GarciaRolf ErlebachDaniel Andrea HofmaennerGiovanni CamenReto Andreas SchuepbachChristoph JüngstBeat MüllhauptJan BartussekPhilipp Karl BuehlerRea AndermattSascha David

Published in: Critical care (London, England) (2022)

A causally plausible, dose-effect relationship between long-term infusion of ketamine and rising total bilirubin levels, as well as an augmented, ketamine-associated, hazard of cholestatic liver injury in critically ill COVID-19 patients could be shown. High-dose ketamine should be refrained from whenever possible for the long-term analgosedation of mechanically ventilated COVID-19 patients.

Keyphrases

liver injury
drug induced
acute respiratory distress syndrome
sars cov
pain management
high dose
extracorporeal membrane oxygenation
low dose
mechanical ventilation
coronavirus disease
oxidative stress
chronic pain
stress induced